Tivic Health Partners with Fletcher Spaght to Accelerate ncVNS Commercial Strategy

Valion Bio, Inc.

Partnered with Fletcher Spaght, a healthcare growth strategy firm, to develop commercial strategy for non-invasive cervical vagus nerve stimulation (ncVNS).
Fletcher Spaght identified ~30 potential use cases in neurologic, cardiac, psychiatric, and autonomic diseases.
Global VNS market projected to grow from $8.59B (2021) to $21.3B (2030) at 10.6% CAGR; peripheral nerve stimulation at 35% CAGR.
Tivic completed Phase 1 trial showing strong physiological effects in neurological, cardiac, and autonomic systems.
Company expects insights to drive clinical strategy and product development in 2025 and beyond.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.